The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer.

ABSTRACT: During the last two decades, next-generation sequencing (NGS) has played a key role in enhancing non-small cell lung cancer treatment paradigms through the application of "targeted therapy" in advanced and metastatic disease. The use of specific tyrosine kinase inhibitors in patients with oncogenic driver alterations, such as EGFR, ALK, ROS1, BRAF V600E, MET, and NTRK mutations, among others, has changed treatment approaches and improved outcomes in patients with late-stage disease. Although NGS technology has mostly been used in the setting of systemic therapy to identify targets, response to therapy, and mechanisms of resistance, it has multiple potential applications for patients with earlier-stage disease, as well. In this review, we discuss th

SUBMITTER: Lengel HB 

PROVIDER: S-EPMC8345160 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature